结合PI3K和MAPK抑制作用的协同作用抑制了PDAC
bioRxiv : the preprint server for biology
|August 30, 2023
概括
用Omipalisib和Trametinib针对MAPK和PI3K-AKT通路显著改善了胰腺癌模型中的生存率. 这种双重治疗策略为胰腺管道腺癌 (PDAC) 治疗提供了一个有希望的方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰腺管道腺癌 (PDAC) 具有KRAS突变的特征,导致对单途径向疗法的耐药性.
- 目前针对KRAS或MAPK通路影响者的现有治疗方法由于药物耐药性和PI3K-AKT等替代通路的激活,表现出有限的成功.
研究的目的:
- 评估双重向疗法的疗效,在PDAC中将Omipalisib (PI3K-AKT抑制剂) 与Trametinib (MEK抑制剂) 或SHP099 (SHP2抑制剂) 结合在一起.
- 在PDAC进展中研究抑制MAPK和PI3K-AKT信号通路的协同效应.
主要方法:
- 在体外研究中评估了使用组合疗法 (奥米帕利西布/特拉美提尼布,奥米帕利西布/SHP099) 的细胞增殖,殖民地形成和迁移.
- 在体内研究评估了用Omipalisib/SHP099和Omipalisib/Trametinib在小鼠模型中的瘤生长.
- 在自发PDAC小鼠模型 (PKT) 中进一步测试了Omipalisib/Trametinib的疗效.
主要成果:
- 单剂疗法部分抑制了ERK或AKT酸化,一些药物增加了补偿通路活性.
- 组合疗法 (奥米帕利西布/特拉美提尼布和奥米帕利西布/SHP099) 在减少PDAC细胞增殖,殖民地形成和迁移方面表现出卓越的疗效.
- 与Omipalisib/SHP099.9相比,Omipalisib/Trametinib在体内减少瘤生长方面显示出显著更大的有效性.
- 在PKT小鼠模型中,Omipalisib/Trametinib联合治疗显著延长了生存时间,与对照组相比,平均生存时间翻了一番以上.
结论:
- 同时针对MAPK和PI3K-AKT通路对于有效的PDAC治疗至关重要.
- 奥米帕利西布和特拉美替尼布的组合代表了胰腺癌的强有力的治疗策略,在临床前模型中显示出显著的生存益处.
更多相关视频
06:21Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
11.2K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.0K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
